Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · March 10, 2016

Single-Agent Capecitabine Increases Progression-Free Survival in mCRC

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Single-Agent Capecitabine as Maintenance Therapy After Induction of XELOX (or FOLFOX) in First-Line Treatment of Metastatic Colorectal Cancer: Randomized Clinical Trial of Efficacy and Safety
Ann. Oncol 2016 Mar 02;[EPub Ahead of Print], HY Luo, YH Li, W Wang, ZQ Wang, X Yuan, D Ma, FH Wang, DS Zhang, DR Lin, YC Lin, J Jia, XH Hu, JW Peng, RH Xu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading